Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.54 |
| ▸ | CDK1 | P06493 | 8/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.54 |
| ▸ | CDK9 | P50750 | 7/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.54 |
| ▸ | JAK2 | O60674 | 6/20 | 0.52 |
| ▸ | JAK3 | P52333 | 6/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.52 |
| ▸ | TYK2 | P29597 | 5/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.52 |
| ▸ | SYK | P43405 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801913 | 0.88 | CDK9 (0.53) | CDK2CDK1CDK5CDK9CCNT1 | |
| SCHEMBL12801962 | 0.83 | CDK2 (0.46) | CDK2CDK1CDK5CDK9CCNT1 | |
| SCHEMBL2585171 | 0.82 | EIF2AK4 (0.55) | CDK2CDK9JAK2JAK3ALK | |
| SCHEMBL12802007 | 0.81 | EIF2AK4 (0.53) | CDK2CDK1CDK5CDK9CCNT1 | |
| SCHEMBL12797028 | 0.79 | EIF2AK4 (0.51) | CDK2CDK1CDK5CDK9CCNT1 | |
| SCHEMBL1662621 | 0.78 | EIF2AK4 (0.52) | CDK2CDK1CDK5CDK9CCNT1 | |
| SCHEMBL342837 | 0.77 | CDK1 (0.49) | CDK2CDK1CDK5CDK9CCNT1 | |
| SCHEMBL12797150 | 0.76 | PTK2 (0.54) | JAK2JAK3ALKMAPK13MAPK8 | |
| SCHEMBL12796009 | 0.76 | EIF2AK4 (0.56) | CDK2CDK9JAK2JAK3ALK | |
| SCHEMBL12797314 | 0.76 | EIF2AK4 (0.56) | CDK2CDK9JAK2JAK3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | claimed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | claimed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CDK2 198/4885CDK1 30/4885CDK5 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.